Drug Price Negotiation And Part B: Not Much Impact In Year One

 
• By Michael McCaughan
  
Part B impacted some products' inclusion in Medicare price negotiation, but maybe not as much as expected. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from United States